Park Square has placed Monica Gostissa, Ph.D. as Chief Scientific Officer at Matrisome Bio. Matrisome Bio is the world leader in harnessing the distinctive properties of the extracellular matrix (ECM) to revolutionize targeted therapies across chronic diseases.

Gostissa is a seasoned scientific leader with over two decades of experience in oncology and immunotherapy research, spanning academic, biotech, and clinical-stage pharmaceutical settings. She most recently led all aspects of research as Chief Scientific Officer at Egle Therapeutics. Prior to that, she spent six years at Jounce Therapeutics, where she rose through leadership roles to become Vice President and Head of Preclinical Sciences. 

Earlier in her career, Gostissa held scientific leadership roles at Agenus and 121 Bio. Her academic foundation includes a decade of research at Harvard Medical School and Children’s Hospital Boston. 

Originally from Italy, Gostissa earned her B.S. and M.S. in Biological Sciences from the University of Trieste. She received her Ph.D. in Molecular Genetics from the International School of Advanced Studies (SISSA).